← Back to Search

CD73 inhibitor

GET73 for Alcoholism

Phase 1 & 2
Recruiting
Led By James Prisciandaro
Research Sponsored by Medical University of South Carolina
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Currently not engaged in, and does not want treatment for, alcohol-related problems
Be between 18 and 65 years old
Must not have
Currently taking medication known to affect alcohol intake (e.g., disulfiram, naltrexone, acamprosate, topiramate)
Neurological disease or history of head injury with > 2 minutes of unconsciousness.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to day 7

Summary

This trial tests a drug called GET73 on people who drink alcohol regularly but aren't looking for treatment. Participants will take the drug for a short period and have several study visits.

Who is the study for?
This trial is for individuals aged 21-40 with a current Alcohol Use Disorder of at least moderate severity, who drink on average at least 20 alcoholic drinks per week. They must live within 50 miles of the study site and be able to abstain from alcohol before appointments. Exclusions include use of certain drugs, major psychiatric disorders, significant medical issues, pregnancy or not using birth control, pending violent crime charges, metal in body preventing MRI scans, severe claustrophobia or obesity.
What is being tested?
The study tests GET73's effects on regular alcohol drinkers who aren't seeking treatment. Participants will take either GET73 or a placebo over an eight-day period and attend four study visits that include two MRI scans to observe any changes in brain activity related to alcohol consumption.
What are the potential side effects?
While specific side effects are not listed here for GET73 or the placebo, common concerns may involve reactions similar to other medications affecting brain chemistry such as headaches, dizziness, nausea or changes in mood and behavior.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am not seeking treatment for alcohol-related issues.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am on medication that influences how much alcohol I drink.
Select...
I have a neurological condition or had a head injury that made me unconscious for more than 2 minutes.
Select...
I am currently taking medication for mental health or seizures.
Select...
I am not pregnant, nursing, and I use reliable birth control.
Select...
I have been diagnosed with a mental health condition like depression or schizophrenia.
Select...
I haven't used drugs except for marijuana and nicotine recently.
Select...
My liver tests are more than 2.5 times the normal level.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to day 7
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to day 7 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Gamma aminobutyric acid (GABA) and glutamate levels
Levels of cortical activation to visual cues of alcohol

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Group BExperimental Treatment1 Intervention
Group II: Group APlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
GET73
2018
Completed Phase 2
~30

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for alcoholism often target neurological pathways to reduce alcohol consumption and prevent relapse. Naltrexone works by blocking opioid receptors, which reduces the rewarding effects of alcohol and decreases cravings. Acamprosate modulates glutamate and GABA neurotransmission, helping to restore the balance disrupted by chronic alcohol use, thus reducing withdrawal symptoms and cravings. Disulfiram inhibits the enzyme acetaldehyde dehydrogenase, causing unpleasant effects when alcohol is consumed, thereby deterring drinking. These treatments are crucial for patients as they address the neurological underpinnings of addiction, making it easier to maintain sobriety and improve overall quality of life.

Find a Location

Who is running the clinical trial?

Medical University of South CarolinaLead Sponsor
969 Previous Clinical Trials
7,399,267 Total Patients Enrolled
46 Trials studying Alcoholism
5,001 Patients Enrolled for Alcoholism
National Institutes of Health (NIH)NIH
2,810 Previous Clinical Trials
8,159,559 Total Patients Enrolled
32 Trials studying Alcoholism
7,778 Patients Enrolled for Alcoholism
National Institute on Alcohol Abuse and Alcoholism (NIAAA)NIH
835 Previous Clinical Trials
1,082,771 Total Patients Enrolled
456 Trials studying Alcoholism
823,683 Patients Enrolled for Alcoholism

Media Library

GET73 (CD73 inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04831684 — Phase 1 & 2
Alcoholism Research Study Groups: Group A, Group B
Alcoholism Clinical Trial 2023: GET73 Highlights & Side Effects. Trial Name: NCT04831684 — Phase 1 & 2
GET73 (CD73 inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04831684 — Phase 1 & 2
~28 spots leftby Apr 2026